Let's recap, what happened last couple of weeks to see the drop from 10c to 7.5c:
Let's speak the truth. The market is strong, particularly in the biotech sector. Imugene management have consistently blamed macroeconomic conditions and volatility in the biotech sector for their underperformance. Now who do they blame?
Capital raises are taking place at a premium to the prevailing share price (i.e., ACW - ASX). Transparency is being afforded to shareholders visa vie the CEO's of biotech companies (i.e., NEU - ASX). Clear and concise details and information pertaining to clinical trials, the timeline for data releases and correspondence from regulators is the benchmark.
Conversely, having noted data would be released at major conferences, then having stated important clinical trial results were "COMING SOON" at such medical convention's, Imugene have failed to notify shareholders of results from scan after scan in a clinical trial they have noted they are prioritising. It goes without saying IMU investors are no longer interested in the one patient who attained a complete response in the ongoing Vaxinia (MAST) Trial. They are interested in the other 46 patients dosed in the trial. In particular the 20 patients remaining in treatment after multiple scans thus far.
The market hopped on board with Imugene in the company's initial capital raises. Investors were buoyed by Imugene's entry into the lucrative lung cancer market, with the company's PD1 Vaxx vaccine showing so much promise in its initial Phase 1 hit out. Though once again communication from management has been found wanting, as the PD1 Vaxx combination trial with Roche Therapeutics Tercentriq has not been spoken of for close to a year now, since it entered the clinic.
Unfortunately Leslie Chong, Paul Hopper and the IMU board in general only have themselves to blame for their recent fall from grace, having shown so much promise in November 2023. In retrospect how they failed to capitalise on such stellar results from their Vaxinia (MAST) Trial back then is beyond me. It's only a matter of time before the majority say they aren't prepared to pay Monil Shah and other company representatives anymore. That they as shareholders and owners of the company made a mistake in delivering such generous bonuses and options to their otherwise well paid company representative's. Its surely only a matter of time before they stand up and say they aren't prepared any longer to throw good money after bad. Before they vote to out source the duties internal personnel have failed to deliver on. That's simply put, corporate life. Whilst some may be present to win friends and influence people, on the whole most on a share register are there to make money, irrespective of whose head has to role in between times.
There is much as always to look forward to for those remaining with skin in the game at Imugene (IMU - ASX). But now IMU shareholders must reassess. Management have consistently said they are unaware of why their share price is performing so poorly. They have even suggested at investor conferences and roadshows it is not their duty to sell shares to us as individuals, nor to deliver a strong share price. This has no doubt created a sense of uncertainty amongst the investment community at large.
Given the lack of information at hand it's all about keeping the faith, following the science and continuing to believe there are brighter days ahead, for those who hold and remain steadfast to the cause. If only the goal posts didn't keep changing they may have something to hold onto.
DYOR Seek investment advice as and when required Opinions only
Expand
(20min delay)